论文部分内容阅读
目的观察分析同步放化疗治疗Ⅲ期非小细胞肺癌临床疗效。方法选取于我院诊疗的Ⅲ期非小细胞肺癌68例作为研究对象,按照随机抛币法将其分为对照组和观察组,其中对照组34例行序贯放化疗,观察组患者34例行同步放化疗。统计比较两组患者的临床疗效、生存期限以及治疗期间产生的毒副反应。结果观察组患者的总有效率(67.65%)与对照组患者的总有效率(44.12%)差异明显,具有统计学意义(P<0.05)。对照组患者平均生存期限(11.4±3.6)个月与观察组患者平均生存期限(20.1±4.3)个月差异明显,具有统计学意义(P<0.05)。两组患者各项毒副作用比较差异均不具有统计学意义(P>0.05)。结论同步放化疗可以显著的提高Ⅲ期非小细胞肺癌的治疗效果,延长患者的生存期限,且不会增加毒副反应。
Objective To observe and analyze the clinical curative effect of concurrent radiotherapy and chemotherapy for stage III non-small cell lung cancer. Methods Sixty-eight cases of stage III NSCLC treated in our hospital were selected as study subjects. They were randomly divided into a control group and an observation group. Among them, 34 cases received sequential chemotherapy in the control group and 34 cases in the observation group. Synchrotherapy and chemotherapy. Statistically compare the clinical efficacy, survival duration, and the toxicities and side effects produced during the treatment between the two groups of patients. Results The total effective rate (67.65%) in the observation group was significantly different from that in the control group (44.12%), with statistical significance (P<0.05). The mean survival time of the control group (11.4±3.6) months was significantly different from that of the observation group (20.1±4.3) months, with statistical significance (P<0.05). There were no significant differences in the toxic and side effects between the two groups (P>0.05). Conclusion The concurrent radiotherapy and chemotherapy can significantly improve the therapeutic effect of stage III non-small cell lung cancer, prolong the survival period of the patients, and will not increase the toxic side effects.